Chemomab Therapeutics Ltd CMMB Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$1.30 up $0.07, 5.69% at close Nov 5
Last close · Previous close $1.23
- Market cap
- At the Nov 5 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.30up $0.07, 5.69%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.23Nov 4
- Volume28.66KNov 4 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume40.09KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.92 to $2.99; now $1.30
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CMMB trailed the S&P 500 in all 6 periods.
| Period | CMMB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CMMB: down 7.8% S&P 500: down 5.4% | CMMB trailed the S&P 500 by 2.4 percentage points Trailed |
| 3M | CMMB: down 25.7% S&P 500: down 4.5% | CMMB trailed the S&P 500 by 21.2 percentage points Trailed |
| YTD | CMMB: down 21.2% S&P 500: up 8.3% | CMMB trailed the S&P 500 by 29.5 percentage points Trailed |
| 1Y | CMMB: down 51.3% S&P 500: up 9.3% | CMMB trailed the S&P 500 by 60.6 percentage points Trailed |
| Long term | ||
| 3Y | CMMB: down 56.6% S&P 500: up 74.8% −24.3% vs +20.5% a year | CMMB trailed the S&P 500 by 131.4 percentage points Trailed |
| 5Y | CMMB: down 96.7% S&P 500: up 67.3% −49.4% vs +10.8% a year | CMMB trailed the S&P 500 by 164.0 percentage points Trailed |
$10,000 invested in CMMB 5 years ago (Nov 5, 2021) would be worth about $333 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,730.
CMMB trailed the S&P 500 in all 6 periods.
| Period | CMMB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CMMB: down 7.8% S&P 500: down 5.4% | CMMB trailed the S&P 500 by 2.4 percentage points Trailed |
| 3M | CMMB: down 25.7% S&P 500: down 4.8% | CMMB trailed the S&P 500 by 20.9 percentage points Trailed |
| YTD | CMMB: down 21.2% S&P 500: up 7.5% | CMMB trailed the S&P 500 by 28.7 percentage points Trailed |
| 1Y | CMMB: down 51.3% S&P 500: up 8.2% | CMMB trailed the S&P 500 by 59.5 percentage points Trailed |
| Long term | ||
| 3Y | CMMB: down 56.6% S&P 500: up 68.6% −24.3% vs +19.0% a year | CMMB trailed the S&P 500 by 125.2 percentage points Trailed |
| 5Y | CMMB: down 96.7% S&P 500: up 56.4% −49.4% vs +9.4% a year | CMMB trailed the S&P 500 by 153.1 percentage points Trailed |
$10,000 invested in CMMB 5 years ago (Nov 5, 2021) would be worth about $333 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,645.
All-time high
$691.20
Closing high on . Now 99.8% below that record.
Split-adjusted daily closes since Feb 12, 2019.
Stock splits
2
Latest: 1-for-4 on . Share counts adjust after each split.
Both splits
- 1-for-4
- 1-for-16
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$7.55M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$3.48M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$2.96M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$3.32M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$2.06M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$1.74M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$1.87M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$1.77M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$2.17M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$12.48M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$27.65M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$24.22M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$13.95M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$9.00M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- Not reportedLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flowNot reportedLast 12 months
- Capital spendingNot reportedLast 12 months
Shareholder returns
- Not reportedLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $6.69MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$6.69MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 6.41As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −70.4%Last 12 months
Over the last 12 months, Chemomab Therapeutics lost money: its net loss was 70.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −62.6%Last 12 months
Over the last 12 months, Chemomab Therapeutics’s net loss was 62.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Chemomab Therapeutics Ltd
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025 -- FDA feedback on the design of its planned CM-101 PSC registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Israel
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CMMB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CMMB stock FAQ
What is CMMB stock’s price today?
Chemomab Therapeutics (CMMB) traded at $1.30 at the close on , up $0.07 (5.69%) from the previous close of $1.23. Over the past 52 weeks it has traded between $0.92 and $2.99.
If you invested $1,000 in CMMB 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CMMB on would be worth about $33 at the close on , a total return of −96.7%. The same $1,000 would be worth $487 if invested one year ago. Past performance doesn’t predict future returns.
Does CMMB pay a dividend?
Chemomab Therapeutics hasn’t paid a dividend in the last twelve months.
What is CMMB’s 52-week high and low?
Over the past 52 weeks CMMB has traded as low as $0.92 and as high as $2.99. At $1.30 at the close on , it is 56.5% below that high and 41.3% above the low.
What is CMMB’s all-time high?
CMMB’s highest closing price was $691.20 on , adjusted for stock splits. At $1.30 at the close on , it is 99.8% below that record.
Has CMMB stock ever split?
Yes, twice: 1-for-16 on ; 1-for-4 on .
How has CMMB stock performed?
Including dividends and measured to the close on , CMMB has returned −21.2% so far this year and −51.3% over the past year, and −96.7% over five years (−49.4% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Chemomab Therapeutics in?
Chemomab Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Israel.
What exchange does CMMB trade on?
Chemomab Therapeutics trades on the Nasdaq under the ticker symbol CMMB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.